{"nctId":"NCT04308590","briefTitle":"A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas","startDateStruct":{"date":"2020-07-27","type":"ACTUAL"},"conditions":["Hypercortisolism"],"count":137,"armGroups":[{"label":"Relacorilant","type":"EXPERIMENTAL","interventionNames":["Drug: Relacorilant","Other: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Relacorilant","otherNames":["CORT125134"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Shows lack of cortisol suppression on dexamethasone suppression test\n* Suppressed or low early-morning adrenocorticotropic hormone (ACTH) levels\n* A radiologically confirmed adrenal lesion\n* Has IGT or DM\n* Has uncontrolled HTN\n\nExclusion Criteria:\n\n* Has severe, uncontrolled HTN\n* Has poorly controlled DM\n* Has DM Type 1\n* Has significantly abnormal liver test results or severe renal insufficiency\n* Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Average 24-hour SBP","description":"Blood pressure was measured by 24-hour ABPM. The 24-hour average SBP is reported.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":null},{"groupId":"OG001","value":"-2.89","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Area Under the Concentration-time Curve of Blood Glucose (AUCglucose)","description":"AUCglucose was calculated based on results of the plasma 2-hour oGTT.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.566","spread":null},{"groupId":"OG001","value":"1.008","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Average Diastolic Blood Pressure (DBP)","description":"Blood pressure was measured by 24-hour ABPM. Daytime average DBP was measured from 06:00 to 21:59. Nighttime average DBP was measure from 22:00 to 05:59.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":null},{"groupId":"OG001","value":"-1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":null},{"groupId":"OG001","value":"-1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":null},{"groupId":"OG001","value":"-0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Average Heart Rate (HR)","description":"Heart rate was measured by 24-hour ABPM. Daytime average HR was measured from 06:00 to 21:59. Nighttime average HR was measure from 22:00 to 05:59.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"-2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"-1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"-2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Average Daytime and Nighttime SBP","description":"Blood pressure was measured by 24-hour ABPM. Daytime average SBP was measured from 06:00 to 21:59. Nighttime average SBP was measure from 22:00 to 05:59.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":null},{"groupId":"OG001","value":"-2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":null},{"groupId":"OG001","value":"-3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin HbA1c for Patients With HbA1c ≥5.7% at Baseline","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c for Patients With HbA1c ≥6.5% at Baseline","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":null},{"groupId":"OG001","value":"-0.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL","description":"Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With IGT Who Achieved 2-hour oGTT Glucose <140 mg/dL","description":"Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Any Dose Decrease in Antihypertensive Medication","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Any Dose Decrease in Diabetes Medication","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Any Dose Increase or Switch in Diabetes Medication","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With HbA1c ≥6.5% at Baseline Who Achieved HbA1c <6.5%","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg)","description":"Blood pressure was measured by 24-hour ABPM Test. Reported is the number of patients with HTN at Baseline who achieved SBP \\<130 mm Hg at Week 22.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg","description":"Blood pressure was measured by 24-hour ABPM. Reported is the number of patients with HTN at Baseline who achieved at least a 5 mm Hg reduction in 24-hour average SBP at Week 22.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":68},"commonTop":["Back pain","Fatigue","Arthralgia","Nausea","Headache"]}}}